Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorChinese PLA General Hospital
About this trial
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Eligibility criteria
Qualifiers
Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
Must have undergone bronchoalveolar lavage.
Age≥18 years old.
Disqualifiers
Patients who had other connective tissue diseases.
Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
Pregnant or lactating patients.
The patient also participated in any other clinical trial.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1PLA100853, BeijingBeijing Municipality, China
Sponsors and collaborators
Chinese PLA General Hospital
Lead sponsor
Source ClinicalTrials.gov